| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Expected but not Quantified |
|---|
| Creation Date | 2006-10-17 11:54:18 UTC |
|---|
| Update Date | 2022-03-07 02:49:25 UTC |
|---|
| HMDB ID | HMDB0005042 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | Aripiprazole |
|---|
| Description | Aripiprazole is a warning has gone out recently because of this drug's name. The '-prazole' ending of this drug name makes this drug sound like it is one of the proton pump inhibitors (such as omeprazole, pantoprazole, lansoprazole) which are used in treating peptic ulcer disease. However, aripiprazole and these drugs are in an entirely different class of drugs altogether and confusing the two can lead to some unnecessary side effects. Aripiprazole is the sixth and most recent of the atypical antipsychotic medications to be approved by the Food and Drug Administration (FDA) for the treatment of schizophrenia. It has also recently received FDA approval for the treatment of acute manic and mixed episodes associated with bipolar disorder. Aripiprazole appears to mediate its antipsychotic effects primarily by partial agonism at the Dopamine 2 (D2)receptor. |
|---|
| Structure | ClC1=CC=CC(N2CCN(CCCCOC3=CC4=C(CCC(=O)N4)C=C3)CC2)=C1Cl InChI=1S/C23H27Cl2N3O2/c24-19-4-3-5-21(23(19)25)28-13-11-27(12-14-28)10-1-2-15-30-18-8-6-17-7-9-22(29)26-20(17)16-18/h3-6,8,16H,1-2,7,9-15H2,(H,26,29) |
|---|
| Synonyms | | Value | Source |
|---|
| Abilify | ChEBI | | Abilitat | ChEBI | | Aripiprazol | ChEBI | | Aripiprazolum | ChEBI | | 7-(4-(4-(2,3-Dichlorophenyl)-1-piperazinyl)butyloxy)-3,4-dihydro-2(1H)-quinolinone | HMDB |
|
|---|
| Chemical Formula | C23H27Cl2N3O2 |
|---|
| Average Molecular Weight | 448.385 |
|---|
| Monoisotopic Molecular Weight | 447.148032537 |
|---|
| IUPAC Name | 7-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy}-1,2,3,4-tetrahydroquinolin-2-one |
|---|
| Traditional Name | aripiprazole |
|---|
| CAS Registry Number | 129722-12-9 |
|---|
| SMILES | ClC1=CC=CC(N2CCN(CCCCOC3=CC4=C(CCC(=O)N4)C=C3)CC2)=C1Cl |
|---|
| InChI Identifier | InChI=1S/C23H27Cl2N3O2/c24-19-4-3-5-21(23(19)25)28-13-11-27(12-14-28)10-1-2-15-30-18-8-6-17-7-9-22(29)26-20(17)16-18/h3-6,8,16H,1-2,7,9-15H2,(H,26,29) |
|---|
| InChI Key | CEUORZQYGODEFX-UHFFFAOYSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as phenylpiperazines. Phenylpiperazines are compounds containing a phenylpiperazine skeleton, which consists of a piperazine bound to a phenyl group. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Organoheterocyclic compounds |
|---|
| Class | Diazinanes |
|---|
| Sub Class | Piperazines |
|---|
| Direct Parent | Phenylpiperazines |
|---|
| Alternative Parents | |
|---|
| Substituents | - Phenylpiperazine
- N-arylpiperazine
- Tetrahydroquinolone
- Quinolone
- Tetrahydroquinoline
- 1,2-dichlorobenzene
- Tertiary aliphatic/aromatic amine
- Aniline or substituted anilines
- Dialkylarylamine
- Alkyl aryl ether
- Halobenzene
- Chlorobenzene
- N-alkylpiperazine
- Monocyclic benzene moiety
- Aryl halide
- Aryl chloride
- Benzenoid
- Carboxamide group
- Secondary carboxylic acid amide
- Amino acid or derivatives
- Tertiary amine
- Tertiary aliphatic amine
- Lactam
- Azacycle
- Carboxylic acid derivative
- Ether
- Organonitrogen compound
- Organooxygen compound
- Amine
- Organic nitrogen compound
- Carbonyl group
- Hydrocarbon derivative
- Organic oxide
- Organopnictogen compound
- Organic oxygen compound
- Organochloride
- Organohalogen compound
- Aromatic heteropolycyclic compound
|
|---|
| Molecular Framework | Aromatic heteropolycyclic compounds |
|---|
| External Descriptors | |
|---|
| Ontology |
|---|
| Physiological effect | |
|---|
| Disposition | |
|---|
| Process | Not Available |
|---|
| Role | |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | Not Available | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | Not Available | Not Available | | LogP | Not Available | Not Available |
|
|---|
| Experimental Chromatographic Properties | Experimental Collision Cross Sections |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 5.63 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 12.6039 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 2.59 minutes | 32390414 | | AjsUoB = Accucore 150 Amide HILIC with 10mM Ammonium Formate, 0.1% Formic Acid | 39.5 seconds | 40023050 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 1651.3 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 206.1 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 204.8 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 174.3 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 124.7 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 518.3 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 517.6 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 152.6 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 1133.5 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 442.6 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 1535.0 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 376.7 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 352.5 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 301.5 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 191.2 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 7.9 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| Aripiprazole,1TMS,isomer #1 | C[Si](C)(C)N1C(=O)CCC2=CC=C(OCCCCN3CCN(C4=CC=CC(Cl)=C4Cl)CC3)C=C21 | 3727.4 | Semi standard non polar | 33892256 | | Aripiprazole,1TMS,isomer #1 | C[Si](C)(C)N1C(=O)CCC2=CC=C(OCCCCN3CCN(C4=CC=CC(Cl)=C4Cl)CC3)C=C21 | 3717.3 | Standard non polar | 33892256 | | Aripiprazole,1TMS,isomer #1 | C[Si](C)(C)N1C(=O)CCC2=CC=C(OCCCCN3CCN(C4=CC=CC(Cl)=C4Cl)CC3)C=C21 | 4628.5 | Standard polar | 33892256 | | Aripiprazole,1TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)N1C(=O)CCC2=CC=C(OCCCCN3CCN(C4=CC=CC(Cl)=C4Cl)CC3)C=C21 | 3947.9 | Semi standard non polar | 33892256 | | Aripiprazole,1TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)N1C(=O)CCC2=CC=C(OCCCCN3CCN(C4=CC=CC(Cl)=C4Cl)CC3)C=C21 | 3947.8 | Standard non polar | 33892256 | | Aripiprazole,1TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)N1C(=O)CCC2=CC=C(OCCCCN3CCN(C4=CC=CC(Cl)=C4Cl)CC3)C=C21 | 4655.4 | Standard polar | 33892256 |
|
|---|
| GC-MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted GC-MS | Predicted GC-MS Spectrum - Aripiprazole GC-MS (Non-derivatized) - 70eV, Positive | splash10-0w4i-1490100000-261de3e19904b78dcdc2 | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Aripiprazole GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Experimental LC-MS/MS | LC-MS/MS Spectrum - Aripiprazole LC-ESI-qTof , Positive-QTOF | splash10-000i-3970100000-6b98b53e8175df39986e | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Aripiprazole , positive-QTOF | splash10-0f72-0340900000-34d93478ad0d9f5cf2b0 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Aripiprazole , positive-QTOF | splash10-000i-3970100000-6b98b53e8175df39986e | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Aripiprazole 35V, Positive-QTOF | splash10-000b-0280900000-b9247c5494e58e66124c | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Aripiprazole 35V, Negative-QTOF | splash10-0006-0190000000-f292c098f875dc5bf103 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Aripiprazole 10V, Positive-QTOF | splash10-0002-0130900000-09f4b35bcf7ec5b72e81 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Aripiprazole 20V, Positive-QTOF | splash10-000j-0691700000-856146a0ee910fc8c54b | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Aripiprazole 40V, Positive-QTOF | splash10-000b-3950000000-13c06e4b3b715a51d3e4 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Aripiprazole 10V, Negative-QTOF | splash10-0002-0400900000-00ad2c66f6eb650acc11 | 2016-08-04 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Aripiprazole 20V, Negative-QTOF | splash10-03dl-2900400000-2f2ae13359ce2017c979 | 2016-08-04 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Aripiprazole 40V, Negative-QTOF | splash10-0006-5900000000-0638ccc974f117bcfc43 | 2016-08-04 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Aripiprazole 10V, Positive-QTOF | splash10-0002-0000900000-80596c933df60e9bbd28 | 2021-09-23 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Aripiprazole 20V, Positive-QTOF | splash10-0002-0011900000-850b35a9d8f2a8e5dbe6 | 2021-09-23 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Aripiprazole 40V, Positive-QTOF | splash10-006t-3920200000-00b90fd36a9ef68756de | 2021-09-23 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Aripiprazole 10V, Negative-QTOF | splash10-0002-0000900000-ac7e0802ed0bc5c520a7 | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Aripiprazole 20V, Negative-QTOF | splash10-0002-2000900000-2fd89cebd272760b7445 | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Aripiprazole 40V, Negative-QTOF | splash10-03e9-6920100000-943ee90010dfdaceadee | 2021-09-24 | Wishart Lab | View Spectrum |
|
|---|